We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
27 April 2020
On 11 March 2020 the World Health Organisation declared the COVID-19 outbreak a global pandemic. As a result, both domestic and international research and development (R&D) efforts regarding related diagnosis and treatment methods are in full swing. To promote and protect the results of this R&D, the Taiwan Intellectual Property Office (TIPO) has verified the Taiwanese patent database by comparing it with the COVID-19-related clinical trials currently registered in the US clinical trial database.
Further, on 13 March 2020 TIPO released current Taiwanese patent information regarding COVID-19-related clinical trial drugs for public reference. According to the announcement, this information covers:
Making the above information public will benefit pharmaceutical companies and help with patent planning for COVID-19 diagnosis and treatment method R&D. It will also help to avoid redundant resource allocation and other wasted resources. Therefore, pharmaceutical companies and research organisations should pay attention to this development.
For further information on this topic please contact Tsung-Yuan Shen at Lee and Li Attorneys at Law by telephone (+886 2 2763 8000) or email (email@example.com). The Lee and Li website can be accessed at www.leeandli.com.
(1) Further information is available on the TIPO website.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.